Irenic Capital Management LP — THERAVANCE BIOPHARMA INC TBPH: Quarterly 13F Position History
Irenic Capital Management LP has reported THERAVANCE BIOPHARMA INC (TBPH) on 14 13F-HR filings in Pactolio's tracked window, first appearing in Q4 2022. As of Q1 2026, the position is sized at 2,760,948 shares ($44.8M market value, 4.06% of the equity book).
- 2,760,948Shares Held (Latest Filing)
- $44.8MReported Market Value (Latest Filing)
- 4.06%Portfolio Weight (% of 13F Equity Book)
- 0Quarter-over-Quarter Share Change
- -$6.8MQuarter-over-Quarter Value Change
- 2,764,048Peak Reported Shares (Historical)
Quarterly 13F-HR Disclosure History Source: SEC 13F-HR filings, 14 quarter s
| Quarter | Shares | QoQ Share Change | Share Change (%) | Market Value | Weight | Implied Price |
|---|---|---|---|---|---|---|
| Q1 2026 | 2,760,948 | 0 | — | $44.8M | 4.06% | $16.23 |
| Q4 2025 | 2,760,948 | 0 | — | $51.7M | 6.77% | $18.71 |
| Q3 2025 | 2,760,948 | 0 | — | $40.3M | 7.92% | $14.60 |
| Q2 2025 | 2,760,948 | 0 | — | $30.5M | 6.70% | $11.03 |
| Q1 2025 | 2,760,948 | 0 | — | $24.7M | 3.74% | $8.93 |
| Q4 2024 | 2,760,948 | 0 | — | $26.0M | 3.96% | $9.41 |
| Q3 2024 | 2,760,948 | 0 | — | $22.3M | 3.90% | $8.06 |
| Q2 2024 | 2,760,948 | 0 | — | $23.4M | 5.68% | $8.48 |
| Q1 2024 | 2,760,948 | 0 | — | $24.8M | 6.34% | $8.97 |
| Q4 2023 | 2,760,948 | 0 | — | $31.0M | 6.72% | $11.24 |
| Q3 2023 | 2,760,948 | 0 | — | $23.8M | 7.31% | $8.63 |
| Q2 2023 | 2,760,948 | 3,100 | -0.1% | $28.6M | 9.80% | $10.35 |
| Q1 2023 | 2,764,048 | +1,063,111 | +62.5% | $30.0M | 12.47% | $10.85 |
| Q4 2022 | 1,700,937 | — | — | $19.1M | 10.13% | $11.22 |
Methodology & FAQ
How This Position History Is Sourced
Each row is one SEC Form 13F-HR filing disclosing this position. Share count, market value, and reported quarter are taken verbatim from the filing; portfolio weight is recomputed against the same filing's total reported equity book. Implied price-per-share is market value divided by shares — a quarter-end mark, not the manager's cost basis. See the full methodology document for the normalization rules.
When did Irenic Capital Management LP first disclose a TBPH position in 13F-HR filings?
Irenic Capital Management LP first reported THERAVANCE BIOPHARMA INC (TBPH) on its 13F-HR filing for the period ending 2022-12-31 (Q4 2022). The position has appeared on 14 reported quarters within Pactolio's tracked window.
What was Irenic Capital Management LP's most recent quarter-over-quarter share-count change in TBPH?
Irenic Capital Management LP held the same 2,760,948 shares of TBPH between Q4 2025 and Q1 2026 — the reported share count was unchanged quarter-over-quarter.
Does the implied price-per-share represent Irenic Capital Management LP's cost basis in TBPH?
No. The implied price-per-share column is the 13F-HR reported market value divided by reported share count on the filing date (end of quarter). It is a quarter-end mark, not a cost basis or transaction price. Use it as a sanity check on the value column, not as an indicator of the manager's entry or exit price.